Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
PLN 34
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Medinice S.A. provides medical solution for cardiology and cardiac surgery. The company support scientists for product commercialization including prototyping, clinical trials and certification, and product sales. Medinice S.A. was founded in 2012 and is based in Warsaw, Poland.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBIT
Data is available to registered users only
